Drs. Jamil Asselah, Rami Younan, and Kim Ma review major Day 1 updates from ESMO 2025 in early breast cancer—monarchE overall survival, 5-year NATALEE, and POSITIVE trial results—while previewing upcoming data in neoadjuvant, post-neoadjuvant, and metastatic settings to be discussed in the days ahead.
